Description
Anti-TROP-2 Antibody, ADCC Enchanced (BioBet-CB-046LX) is a glycosylation-modified anti-TROP-2 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TROP-2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TROP-2
Full Name
Cell surface glycoprotein Trop-2
Background
This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals. Mutations of this gene have been associated with gelatinous drop-like corneal dystrophy.[provided by RefSeq, Dec 2009]
Alternative Names
Tumor-associated calcium signal transducer 2; Cell surface glycoprotein Trop-2; TACSTD2 GA733-1; M1S1; TROP2
Gene ID
4070
UniProt ID
P09758
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-046LX
Description
ADCC-Enhanced Anti-Human TROP-2 (Sacituzumab) Antibody is derived from clone Sacituzumab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the TROP-2, and it is intended for the research of Triple-neg. breast cancer.
Antibody Indication
Triple-neg. breast cancer
Triple-neg. breast cancer
